UK markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.7900-0.0300 (-1.65%)
At close: 04:00PM EST
1.7900 0.00 (0.00%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.8200
Open1.8100
Bid1.7800 x 2200
Ask1.7900 x 1400
Day's range1.7700 - 1.8400
52-week range1.4500 - 6.3200
Volume1,213,767
Avg. volume1,479,988
Market cap296.916M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings date10 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.58
  • Globe Newswire

    atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

    GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta

  • Globe Newswire

    atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

    NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Sc

  • Globe Newswire

    atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

    - This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 - KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models - An assessment of the respiratory impact of KUR-101 was inconclusive as the positive control, oxycodone, failed to separate from placebo - KUR-101, a deuterated derivative of mitragynine, is a low-potency, partial mu-opioid receptor (MOR) agonist designed to prod